- A new blood test shows promise in accurately detecting ovarian cancer at its earliest stages, potentially transforming patient care.
- Developed by AOA Dx, the innovative test identifies two distinct blood markers and uses machine learning to recognise subtle patterns of lipids and proteins shed by cancer cells.
- Studies demonstrated high accuracy, with the test detecting ovarian cancer across all stages with 93 per cent accuracy in Colorado samples and 92 per cent in Manchester samples.
- Experts are optimistic that, pending regulatory approval, this test could be integrated into NHS services, offering a significant improvement over current diagnostic methods.
- Ovarian cancer affects approximately 7,500 women in the UK annually, predominantly those over 50, and is often diagnosed too late when it is harder to treat.
IN FULL
